PERSON
Lantheus’ Phase 3 SPLASH Trial Results: 177Lu-PNT2002 Shows Promise but May Not Overtake Pluvicto
Lantheus, Phase 3 SPLASH Trial, 177Lu-PNT2002, PSMA-positive metastatic castration-resistant prostate cancer, ESMO Congress 2024, Pluvicto
Novo Nordisk and Korro Bio Collaborate on $530M RNA Editing Deal for Cardiometabolic Diseases
Novo Nordisk, Korro Bio, RNA editing, cardiometabolic diseases, genetic medicines, pharmaceutical partnerships
FDA Approves Ebglyss (Lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis in Adults and Children 12 Years and Older
Ebglyss, Lebrikizumab-lbkz, FDA Approval, Moderate-to-Severe Atopic Dermatitis, Eczema Treatment
FDA Approves Ocrevus Zunovo: A Breakthrough Subcutaneous Injection for Multiple Sclerosis
Ocrevus Zunovo, FDA Approval, Subcutaneous Injection, Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Primary Progressive Multiple Sclerosis (PPMS), Halozyme Therapeutics, ENHANZE drug delivery technology.
Nuvation Bio Advances with Pooled Data for ROS1-positive Lung Cancer Treatment, Eyes FDA Submission
Nuvation Bio, ROS1-positive NSCLC, taletrectinib, TRUST-I, TRUST-II, FDA submission, lung cancer treatment
Roche Secures FDA Approval for Subcutaneous Ocrevus and Tecentriq, Lilly Gains Approval for Eczema Treatment
FDA approvals, Roche, Subcutaneous products, Ocrevus, Tecentriq, Lilly, Eczema treatment, Pharmaceutical industry, Biopharma news
Revolutionizing Drug Discovery: AI-Driven Solutions for Efficient and Personalized Treatments
Artificial Intelligence (AI) in Drug Discovery, Machine Learning (ML) for Drug Development, Quantum Computing in Pharmaceutical Research, Personalized Medicine, Efficient Drug Discovery Processes, AI-Driven Target Identification and Validation, Quantum Machine Learning (QML) for Drug Discovery
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
F2G Secures $100M Funding for Second Attempt at FDA Approval for Novel Antifungal Drug Olorofim
F2G, antifungal drug, olorofim, FDA approval, funding, second attempt
Adicet Bio Expands into Autoimmune Diseases with Allogeneic Gamma Delta T Cell Therapy
Adicet Bio, Autoimmune diseases, Allogeneic gamma delta T cell therapy, Lupus nephritis, Systemic lupus erythematosus (SLE), Cell therapy